Literature DB >> 15912033

Surgical treatment of advanced-stage carcinoid tumors: lessons learned.

J Philip Boudreaux1, Bradley Putty, Daniel J Frey, Eugene Woltering, Lowell Anthony, Ivonne Daly, Thiagarajan Ramcharan, Jorge Lopera, Wilfrido Castaneda.   

Abstract

OBJECTIVE: To evaluate clinical outcomes in a large group of advanced-stage carcinoid patients (stage IV) following multimodal surgical therapy. SUMMARY BACKGROUND DATA: Patients with advanced-stage carcinoid have traditionally experienced poor 5-year survival (18%-30%). Few recent series have evaluated a large number of patients treated with aggressive surgical rescue therapy.
METHODS: This single-center retrospective review analyzes the records of 82 consecutive carcinoid patients treated by the same 2 surgeons, from August 1998 through August 2004 with a 3- to 72-month follow-up.
RESULTS: Surprisingly, one third of 26 (32%) patients were found to have intestinal obstructions; 10 being moribund at presentation. Mesenteric encasement with intestinal ischemia was successfully relieved in 10 of 12 cases. Five of eighty-two "terminal" patients were rendered free of macroscopic disease. Karnofsky performance scores improved from 65 to 85 (P < 0.0001). Two- and four-year survival for patients with no or unilateral liver metastases (n = 23) was 89%, while 2- and 4-year survival for patients with bilateral liver disease (n = 59) was 68% and 52% (P = 0.072), respectively.
CONCLUSION: We think that all patients with advanced-stage carcinoid should be evaluated for possible multimodal surgical therapy. Primary tumors should be resected, even in the presence of distant metastases to prevent future intestinal obstruction. The "wait and see" method of management of this slow-growing cancer no longer has merit. We offer an algorithm for the surgical evaluation and management of these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15912033      PMCID: PMC1357164          DOI: 10.1097/01.sla.0000164073.08093.5d

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  13 in total

Review 1.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

Authors:  K Oberg; L Kvols; M Caplin; G Delle Fave; W de Herder; G Rindi; P Ruszniewski; E A Woltering; B Wiedenmann
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

2.  Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation.

Authors:  B Dousset; O Saint-Marc; J Pitre; O Soubrane; D Houssin; Y Chapuis
Journal:  World J Surg       Date:  1996-09       Impact factor: 3.352

3.  Cytoreductive hepatic surgery for neuroendocrine tumors.

Authors:  G P McEntee; D M Nagorney; L K Kvols; C G Moertel; C S Grant
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

4.  Cytoreductive surgery in patients with advanced-stage carcinoid tumors.

Authors:  Seza A Gulec; Timothy S Mountcastle; Daniel Frey; Jason D Cundiff; Elizabeth Mathews; Lowell Anthony; J Patrick O'Leary; J Philip Boudreaux
Journal:  Am Surg       Date:  2002-08       Impact factor: 0.688

Review 5.  Current management of gastrointestinal carcinoid tumors.

Authors:  Kenneth J Woodside; Courtney M Townsend; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2004 Sep-Oct       Impact factor: 3.452

Review 6.  Ablative therapies for liver metastases of digestive endocrine tumours.

Authors:  D O'Toole; F Maire; P Ruszniewski
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

Review 7.  Surgery for midgut carcinoid.

Authors:  R Sutton; H E Doran; E M I Williams; J Vora; S Vinjamuri; J Evans; F Campbell; M G T Raraty; P Ghaneh; M Hartley; G J Poston; J P Neoptolemos
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

8.  Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.

Authors:  Eugene A Woltering; James M Lewis; P Johnstone Maxwell; Daniel J Frey; Yi-Zarn Wang; John Rothermel; Catherine T Anthony; Douglas A Balster; J Patrick O'Leary; Lynn H Harrison
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

9.  Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?

Authors:  H Chen; J M Hardacre; A Uzar; J L Cameron; M A Choti
Journal:  J Am Coll Surg       Date:  1998-07       Impact factor: 6.113

Review 10.  Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization.

Authors:  D S Diaco; H Hajarizadeh; C R Mueller; W S Fletcher; R F Pommier; E A Woltering
Journal:  Am J Surg       Date:  1995-05       Impact factor: 2.565

View more
  30 in total

1.  Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor.

Authors:  William H Kitchens; Nahel Elias; Lawrence S Blaszkowsky; A Benedict Cosimi; Martin Hertl
Journal:  World J Surg Oncol       Date:  2011-01-31       Impact factor: 2.754

Review 2.  Surgical management of neuroendocrine tumor-associated liver metastases: a review.

Authors:  Miu Yee Chan; Ka Wing Ma; Albert Chan
Journal:  Gland Surg       Date:  2018-02

3.  Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours.

Authors:  Ashley Kieran Clift; Omar Faiz; Adil Al-Nahhas; Andreas Bockisch; Marc Olaf Liedke; Erik Schloericke; Harpreet Wasan; John Martin; Paul Ziprin; Krishna Moorthy; Andrea Frilling
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

Review 4.  AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids.

Authors:  Eric H Liu; Carmen C Solorzano; Laurence Katznelson; Aaron I Vinik; Richard Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-05       Impact factor: 3.443

5.  Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search.

Authors:  Herwig Cerwenka
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

6.  Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.

Authors:  Kendall J Keck; Jessica E Maxwell; Yusuf Menda; Andrew Bellizzi; Joseph Dillon; Thomas M O'Dorisio; James R Howe
Journal:  Surgery       Date:  2016-11-15       Impact factor: 3.982

7.  Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors.

Authors:  Chanjuan Shi; Raul S Gonzalez; Zhiguo Zhao; Tatsuki Koyama; Toby C Cornish; Kenneth R Hande; Ronald Walker; Martin Sandler; Jordan Berlin; Eric H Liu
Journal:  Am J Clin Pathol       Date:  2015-03       Impact factor: 2.493

8.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Authors:  Yuling Xiao; Renata Jaskula-Sztul; Alireza Javadi; Wenjin Xu; Jacob Eide; Ajitha Dammalapati; Muthusamy Kunnimalaiyaan; Herbert Chen; Shaoqin Gong
Journal:  Nanoscale       Date:  2012-11-21       Impact factor: 7.790

Review 9.  Carcinoid tumors.

Authors:  Scott N Pinchot; Kyle Holen; Rebecca S Sippel; Herbert Chen
Journal:  Oncologist       Date:  2008-12-17

Review 10.  [Rectal neuroendocrine tumors: surgical therapy].

Authors:  O Radulova-Mauersberger; S Stelzner; H Witzigmannn
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.